Tammy Meyers to Tuberculosis
This is a "connection" page, showing publications Tammy Meyers has written about Tuberculosis.
Connection Strength
1,879
-
Dolutegravir for children with HIV-associated tuberculosis. Lancet HIV. 2022 09; 9(9):e599-e600.
Score: 0,539
-
Pharmacokinetics and safety of a raltegravir-containing regimen in HIV-infected children aged 2-12 years on rifampicin for tuberculosis. AIDS. 2019 11 15; 33(14):2197-2203.
Score: 0,448
-
Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. PLoS One. 2011 Feb 23; 6(2):e17273.
Score: 0,245
-
HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis. 2009 Jul; 13(7):862-7.
Score: 0,218
-
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis. J Pediatric Infect Dis Soc. 2021 Mar 26; 10(2):201-204.
Score: 0,123
-
Microbiological investigation for tuberculosis among HIV-infected children in Soweto, South Africa. Int J Tuberc Lung Dis. 2014 Jun; 18(6):676-81.
Score: 0,077
-
Antiretroviral therapy for children in resource-limited settings: current regimens and the role of newer agents. Paediatr Drugs. 2011 Oct 01; 13(5):303-16.
Score: 0,064
-
Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther. 2011; 16(3):417-21.
Score: 0,061
-
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2009 Apr 15; 50(5):439-43.
Score: 0,054
-
Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008 Apr 15; 47(5):566-9.
Score: 0,050